The Impact of Adherence and Development of Neutralizing Antibodies to Interferons β on Treatment of Multiple Sclerosis in the Czech Republic.

1 Steinberg SC et al., Clin Drug Investig. 2010;30(2):89-100 • 2 Clerico M et al. Neurol Sci. 2007 Aug 15;259(1-2):104-8 • 3 Sorensen PS et al. Mult Scler. 2008 Jul;14(6):837-42 • 4 Koch-Henriksen N et al. Mult Scler. 2009 May;15(5):601-5 • 5 Paolicelli D et al. J Neurol. 2013 Jun;260(6):1562-8 • 6 Farrell R et al. Mult Scler. 2008 Mar;14(2):212-8 • 7 Devonshire V et al., Eur J Neurol. 2011 Jan;18(1):69-77 • 8 Hegen H et al., Mult Scler. 2012 May;18(5):610-5 • 9 Jacobs LD et al., Ann Neurol. 1996 Mar;39(3):285-94 • 10 PRISMS Study Group., Lancet. 1998 Nov 7;352(9139):1498-504 • 11 The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group, Neurology. 1995 Jul;45(7):1277-85 • 12 Devonshire V et al., Lancet Neurol. 2012 May;11(5):420-8 • 13 Johnson KP et al., Neurology. 1995 Jul;45(7):1268-76 • 14 Polman CH et al., N Engl J Med. 2006 Mar 2;354(9):899-910 • 15 Tappenden P et al., ScHARR, University of Scheffield, 2001 • 16 State Institute of Drug Control. Medicinal products database, 2013 • 17 Vocelka M et al., Farmakoekonomika. 2012;1:29-33 • 18 Tan H et al., Adv Ther. 2011 Jan;28(1):51-61 • 19 Blahova Dusankova J et al., Mult Scler. 2012 May;18(5):662-8 • 20 General Health Insurance Company of the Czech Republic., List of medical services, 2013 • 21 IMS Health Inc., IMS total market sales data, 2013 • 22 Halpern R et al., Patient Prefer Adherence. 2011 Jan 20;5:73-84 • 23 Treadaway K et al., J Neurol. 2009 Apr;256(4):568-76 • 24 Meluzínová E., Zdravotnické noviny. 012;61(3): 20-21 • 25 Farrell RA et al., J Interferon Cytokine Res. 2010 Oct;30(10):715-26 • 26 Hutchinson M et al., Curr Med Res Opin. 2014 Apr;30(4):613-27 CONCLUSIONS